Applied Genetic Technologies Corporation

AGTC is a clinical-stage biotechnology company that uses a proprietary gene therapy platform to develop transformational genetic therapies for patients suffering from rare and debilitating diseases. Our initial focus is on the field of ophthalmology, in which we have active clinical trials in X-linked retinitis pigmentosa (XLRP), in Phase 2/3, and achromatopsia, in Phase 1/2, caused by two different genetic defects. We also have an optogenetics program developed in collaboration with Bionic Sight with a Phase 1/2 trial ongoing. In addition to our clinical trials, AGTC has preclinical programs in other ophthalmology, CNS and otology indications.